Abstract
BackgroundThe receptor for advanced glycation endproducts (RAGE) is an oncogenic multidisciplinary trans-membranous receptor, which is overexpressed in multiple human cancers. Recently, it has been shown that RAGE is also involved in carcinogenesis and tumor invasion. In this study, we investigated the expression levels and prognostic value of RAGE in primary gastric cancers (GC).MethodsWe investigated RAGE expression in primary GC and paired normal gastric tissue by real-time quantitative RT-PCR (n = 30) and Western blotting analysis (n = 30). Additionally, we performed immunohistochemistry on 180 paraffin-embedded GC specimens, 69 matched normal specimens.ResultsRAGE was overexpressed in GC compared with the adjacent noncancerous tissues (P＜0.001), and higher RAGE expression significantly correlated with the histological grade (P = 0.002), nodal status(P = 0.025), metastasis status(P = 0.002), and American Joint Committee on Cancer stage (P = 0.020). Furthermore, upregulation of RAGE expression is an independent prognostic factor in multivariate analysis using the Cox regression model (P = 0.001).ConclusionsRAGE Overexpression may be a useful marker to predict GC progression and poor prognosis.
Highlights
The receptor for advanced glycation end products (RAGE), a cell surface molecule expressed in a range of cell types, is a multiligand member of the immunoglobulin superfamily [1]
RAGE was overexpressed in gastric cancers (GC) compared with the adjacent noncancerous tissues (P
We identified a relationship between RAGE expression and the clinicopathological features of GC, and evaluated the prognostic value of RAGE expression for the postoperative survival of GC patients
Summary
The receptor for advanced glycation endproducts (RAGE) is an oncogenic multidisciplinary trans-membranous receptor, which is overexpressed in multiple human cancers. It has been shown that RAGE is involved in carcinogenesis and tumor invasion. We investigated the expression levels and prognostic value of RAGE in primary gastric cancers (GC). Data Availability Statement: All relevant data are within the paper. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
